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Abstract
Laromustine is a chemotherapeutic sulfonylhydrazine prodrug used in clinical trials
to treat acute myeloid leukemia (AML) and glioblastoma multiforme (GBM). While
treatment of AML with laromustine has more demonstrative clinical success, there are
enough promising data against GBM to pursue additional pre-clinical and clinical
experiments. To determine the synergistic effects caused by treating cultured GBM cells
with laromustine and a library of FDA-approved compounds, a chemical genetic screen was
developed. To optimize the screen, optimal cultured GBM cell seed density, growth period
and maximum well capacity were determined. The treatment period for a lethal dose of
laromustine in cultured GBM cells was found to be 6 hours; causing acute cell death in half
as much time as the treatment with a lethal dose of Temozolomide, the current GBM
treatment. The LD50 for laromustine in cultured GBM cells was observed to be
approximately 700 µM when treated for 6 hours. Using these standards of optimization for
maximum reproducibility, a chemical genetic screen will be used to determine the
synergistic effects of laromustine with a library of characterized small molecules.
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Introduction
Despite numerous advances made in the treatment of cancer, it still remains as one
of the leading causes of death in the United States. Cancer is categorized by ailments caused
by uncontrolled and unregulated growth of abnormal cells in the body. Some of the main
treatment plans for cancer in the United States include radiation therapy, surgical
resection, and chemotherapy. Chemotherapy is the treatment of cancer through the
introduction of chemicals that damage or destroy cancer cells, often insulting normal cells
in the process. While existing chemotherapy is successful in many cases, there are still
numerous treatments left to be discovered, with over 4775 active clinical trials ranging
from phase I to phase IV across the United States (2)
Glioblastomas are highly malignant tumors generally found in the cerebral
hemispheres of the brain. They arise from astrocytes, star-shaped adhesive cells found in
the supportive tissue of the brain. (3). Glioblastomas multiforme, or grade 4 glioblastoma,
is the most common, yet most aggressive form of glioblastoma in humans. Because of the
tumors’ aggressive form and low survival rate of less than a year, successful treatments
have been evading researchers for the last 50 years (4). Current treatments involve
immediate surgical resection of the tumor, followed by treatment within 3-4 weeks with
radiation therapy and concurrent or adjuvant chemotherapy (5). However, treatment
remains difficult because of the complex nature of glioblastoma multiforme in aspects
ranging from varying forms microscopically, grossly, and genetically (4). Research has
estimated that glioblastoma multiforme cells may have mutations in any gene at a rate of 1
in 1,000 cells, making it extremely difficult to target due to its mutating nature (6). Current
research for treatment has spanned many approaches, including immunologic avenues,
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gene therapy, as well as additional chemotherapeutic possibilities, though there has been
little success in extending the mean survival (7,8).
Laromustine (Cloretazine, Onrigin, 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2[(methylamino)carbonyl] hydrazine), is an experimental chemotherapeutic agent used in
clinical trials to combat acute myeloid leukemia (AML) and glioblastoma multiforme
(GBM). Laromustine, a sulfonylhydrazine prodrug, undergoes base-catalyzed activation to
produce 90CE (1,2- bis(methylsulfonyl)-1-(2-chloroethyl)-hydrazine), a chloroethylating
species, and methyl isocyanate, which can carbamoylate thiols and primary amines (Figure
1) . Research demonstrates that 90CE chloroethylates DNA at the O6 position of guanine,
which leads to an interstrand crosslink with cytosine on the opposite strand; these

Figure 1: Decomposition of laromustine to 90CE and methyl isocyante (1)

linkages are considered the lethal lesions that disrupt DNA replication and cause cell death
(9). Data suggest that laromustine produces more than twice the molar yield of DNA cross-
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links compared to common nitrosoureas, lipophilic DNA alkylating agents containing
nitroso and urea groups that are often used in treating gliomas (10,11).
One of the main processes of DNA repair is base excision repair in which enzymes
remove erroneous nitrogenous bases and replace them with the correct base.
Laromustine’s carbomoylating activities has been shown to inhibit the activity of the repair
enzyme DNA polymerase β (Pol β), which is involved in base excision repair (12). Cells
deficient in Pol β have shown hypersensitivity to some crosslinking agents, creating a
possible synergism between laromustine’s 2-chloroethylating species and carbomoylating
species (12,13). At the same time, methyl isocyanate is hypothesized to interfere with
tumor angiogenesis by inducing dissociation of ASK1 from thioredoxin (1,14). Additionally,
it is thought that methyl isocyante may promote cross-linking by 90CE, perhaps through
the inhibition of the DNA repair protein O6- alkylguanine-DNA- alkyltransferase (AGT) or
other DNA repair processes (12,15).
Laromustine has yielded promising preclinical data in cultured neoplastic cells and
in vivo activity against AML. It induces a dose-dependent inhibition of proliferation,
reduction in cell viability and an increase in apoptosis in all samples, effects only enhanced
when combined with the other AML drugs cytarabine or daunorubicin (16,17). In treating
patients with AML, laromustine has been used in phase II trials, which suggest possible
benefits over other chemotherapy drugs. For example, in a trial with 85 poor-risk elderly
patients with previously untreated AML, the overall response rate was 32%; however,
there was no randomized setting during the study which made it impossible to determine if
laromustine was more successful than current treatment strategies (10,18,19). In a
separate study, laromustine combined with cytarabine showed a 37% response rate while
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the control of just cytarabine showed only a 19% response rate. The study was stopped due
to high level of death from myelosuppression with the intent of continuing the trial with
lower dosages due to its response success (16). Clinical trials suggest that laromustine
should be investigated further with other non-traditional cytotoxic agents with a lack of
toxicity that may synergistically extend the benefits of laromustine (16).
Currently, the median survival for an adult with glioblastoma is 14.6 months with
concurrent radiation therapy and treatment with temozolomide, an alkylating
chemotherapeutic agent that passes through the blood-brain barrier (20). Previous
research has been done regarding the treatment of glioblastoma patients with laromustine;
however, the results have not proven to be conclusive. Patients who did not respond to
radiation and temozolomide treatment were given laromustine and showed a 6-month
survival rate of 6% with a median progression free survival rate of 6.3 weeks (21,22).
Despite the modest success, laromustine is still being investigated for treatment of GBM
due to its ability, like temozolomide, to pass the blood-brain barrier. Additionally, although
evidence suggests that laromustine and temozolomide are effective in treating patients
with refractory AML, further studies have not been done to examine the effects of partner
drugs with laromustine in GBM treatment (23).
High-throughput screening has become an important tool for researchers, as it
creates an efficient way for them to develop new therapeutic compounds and study their
effects with other known drugs as well as across numerous biochemical pathways. A
chemical genetic screen incorporates the canonical genetics rationale to solve a
biochemical problem. In a typical forward genetic experiment, random mutations are
introduced into a population that is then screened for the desired phenotype. In chemical
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genetics, small molecules that inhibit the activity of gene products are used, instead, to
interfere with biochemical phenomena, and the population is screened for a desired
phenotype. As with traditional genetics experiments, there are two forms of a chemical
genetic screen, forward and reverse. A forward screen can be used to determine which
molecules, and therefore which gene products acted upon by the compounds, produce a
desired phenotype; a library of molecules is examined for a certain phenotype and
individual molecules are then studied to understand the determined phenotype (24).
Reverse screens, alternatively, can be used to validate drug targets; proteins are screened
for their affinity to library compounds then used to observe biological phenomena (25,26).
The results of a chemical genetic screen can provide researchers with information
as to how certain pathways, treatments, and processes react to the introduction of foreign
species with known interactions. Chemical genetic screens have proven successful in many
model systems from cultured tumor cells to zebrafish. To determine inhibitors of the
PI3K/PTEN/Akt signal transduction pathway, a chemical genetic screen was performed on
PTEN lipid phosphatase, a tumor suppressor and negative regulator of PI3K/Akt pathway,
null cells using a library of compounds. Successful inhibitors from the first round of
treatment were studied in depth to determine a set of molecules that successful inhibits the
PI3K/Akt pathway in PTEN null cells, exemplifying the use of the chemical genetic screen
to identify known compounds for novel uses (27). In zebrafish, a chemical genetic screen
was used to identify known compounds that had not been previously known to have cell
cycle activity. The library of 320 compounds was used to find alterations in the mitotic
marker phosphor-histone H3: revealing 14 compounds that may be useful in studying cell
cycle biology and in developing chemotherapeutic agents (28). Most similar to the desired
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results with laromustine, a chemical genetic screen was developed to show synergistic
cytotoxicity in nine different melanoma cell lines. Among the 300 drug combinations
tested, synergy between two known drugs, sorafenib, a multikinase inhibitor, and
diclofenac, a nonsteroidal anti-inflammatory drug, exhibited the most cytotoxicity (29). The
study shows that it is possible to identify previously unknown uses and targets for already
known drugs as well as shows that the discovery of synergistic molecules is possible using
a chemical genetic screen.
To aid researchers in creating screens with a large number of compounds the
National Institutes of Health developed the NIH Clinical Collection from the NIH Small
Molecular Repository. The collection consists of approximately 450 clinically tested, US
Food and Drug Administration approved, compounds. The library has been tested to allow
researchers access to a large number of clinically approved and understood molecules for
high-throughout screening. It has been used in screens to identify previously unknown
uses for the known drugs, such as observing unknown inhibitory effects on adenylyl
cyclase isoforms; experts have expressed medium to high levels of confidence in the
performance of the collection (30,31).
To examine the possibly undiscovered synergistic effects in treating glioblastoma
multiforme between laromustine when paired with compounds from the NIH Clinical
Collection, a forward chemical genetic screen will be performed in which viability of
cultured cells treated with laromustine and the library of compounds is assessed (Figure
2). While laromustine likely has multiple mechanisms of action, as discussed, no bias will
be placed on a particular of the cytotoxic effects; but instead on the effects as a whole. If
molecules are identified, they will be studied more in depth to determine the mechanisms
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behind their synergism with laromustine. Results from this screen could lead to a better
understanding of glioblastoma multiforme and to an improved treatment for the deadly
cancer.

Figure 2: A schematic depicting the overall procedure of the chemical genetic screen to
determine synergistic compounds with laromustine. Cells will be treated with laromustine
and the NIH Clinical Collection separately, and acute cell death will be determined. The
library and laromustine will then be combined for treatment and combinations that show
greater cell death will be studied in depth. (Note: All graphs are predictions. In graph
predicting cell death with library + laromustine, diamond points represent cell death with
just library compound, square represents death with library compound and laromustine,
circled squares represent positive hits for increased cell death.
8

Materials and Methods
U138 Cell Culture Between 25-75% Confluence:
U138 human glioblastoma cells were grown in Eagle Minimum Essential Medium
with 0.1% gentamycin, 1% L-glutamine, and 10% fetal bovine serum. Cells were grown at
37˚C with 5% CO2 and 100% relative humidity.
U138 Cell Seeding
Before each experiment, 80 – 90% confluent U138 cells were washed twice with
0.12 mL/cm2 of HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffered
saline solution (150 mM NaCl, 20 mM HEPES, pH 7.4) and subjected to trypsin/EDTA
(Ethylenediaminetetraacetic acid) for 5 min to detach the cells from the flask. The trypsin
was neutralized using twice the volume of media, and detached cells were centrifuged at
1100 rpm for 5 min. The supernatant was removed, and the cells were re-suspended in 3
mL fresh media. The cells were counted with a Cellometer Auto T4 and viability was
determined using the Trypan blue exclusion assay. Detached U138 cells were incubated in
a 384-well white µClear plate with 25 µL/well at the indicated seed densities for two days
under the aforementioned conditions.
Determination of Optimum Seeding Concentration:
To determine the optimum cell count for the assay, cultured U138 cells were seeded
in quadruplicate at concentrations ranging from 250 cells/ well to 25,000 cells/well (3,000
cells/cm2 – 300,000 cells/cm2) and a negative control without cells, and incubated for two
days. At t = 48 hr, 25 µL of CellTiter-Glo reagent (CellTiter-Glo Luminescent Cell Viability
Assay, Promega, Madison,WI) was added to each well and relative luminescence was
obtained using a Molecular Devices Spectra Max M5 Microplate reader. Data were analyzed
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for average luminescence by quadruplicate and error measured by standard deviation of
quadruplicates.
Determination of U138 Doubling Time and Maximum Cells per Well
To assess the incubation period for U138 cells to double in wells and the maximum
capacity of cells in each well, U138 cells were seeded in triplicate at concentrations ranging
from 250 cells/ well to 25,000 cells/well (3,000 cells/cm2 – 300,000 cells/cm2) and
incubated for two days with a negative control without cells. At time t = 48 hr, 60 hr, 74 hr,
84 hr, 96 hr, 120 hr, 144 hr, and 168 hr, 25 µL of CellTiter-Glo reagent was added to each
well and relative luminescence was obtained. Data were analyzed for average luminescence
by triplicates and error measured by standard deviation of triplicates.
Determination of Incubation Period of laromustine with lethal dose treatment:
To determine the amount of time needed for lethal dose laromustine to cause acute
cell death U138 cells were seeded in triplicate at 5,000 cells/well (60,000 cells/cm2) as
described previously for two days with a negative control without cells. At t = 48 hr, culture
media was aspirated and cells were treated with 25 µL of media containing 1 mM
laromustine, 1 mM temozolomide or the corresponding volume of 1% DMSO by volume. At
each time t = 10 min, 20 min, 30 min, 1 hr, 2 hr, 3 hr, 6 hr, 9 hr, 12 hr, 18 hr, and 24 hr, 25
µL of CellTiter-Glo reagent was added to the wells and relative luminescence was obtained.
Data were analyzed by average luminescence by triplicates and error measured as a
standard deviation of triplicates. Average luminescence across the timescale were
compared to determine time needed for laromustine to cause acute cell death in cultured
U138 cells.
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Determination of 50% Lethal Dose:
To determine the median dose of laromustine is needed to cause 50% acute cell
death, U138 cells were seeded in triplicate at 2500 cells/well (30,000 cells/cm2) as
described previously and incubated for two days with a negative control without cells. At t
= 48 hr, media was aspirated and cells were treated with 25 µL media containing a
concentration of laromustine ranging from 2000 µM to 1 µM in a two-fold serial dilution
with the comparative volume of 1% DMSO by volume as a control. At time t = 6 hr after
seeding, 25 µL of CellTiter-Glo reagent was added to wells and relative luminescence was
obtained. Data were analyzed by average luminescence of triplicates over three trials and
error measured by standard deviation of triplicates. Curve fit analysis was used to
determine the LD50 for laromustine when using cultured U138 cells.
Verification of assay optimization using Temozolomide:
To verify the assay conditions before beginning the screening process,
Temozolomide was used to assess synergistic effects with laromustine. Cultured U138 cells
were seeded in triplicate at 2500 cells/well (30,000 cells/cm2) as described previously and
incubated for two days with a negative control without cells. At t = 48 hr, media was
aspirated and cells were treated with 25 µL media containing a concentration the following
conditions: 1000 µM Temozolomide with 500 µM laromustine and without laromustine,
100 µM Temozolomide with 500 µM laromustine and without laromustine, 100 µM
Temozolomide with 500 µM laromustine and without laromustine, 500 µM laromustine
and a control of 3% DMSO by volume. At time t = 6 hr and t= 12 hr after seeding, 25 µL of
CellTiter-Glo reagent was added to wells and relative luminescence was obtained. Data
were analyzed by average luminescence of triplicates and error measured by standard
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deviation of triplicates. Average luminescence were compared between data for
Temozolomide/laromustine treatments and Temozolomide and laromustine treatments
separately.

Results and Discussion
Cells should be seeded at 2500 cells/well and incubated for 48 hours prior to drug treatment
To ensure that cultured U138 cells are given the sufficient space and time to grow
before drug treatment, the optimal cell seeding concentration was determined. This would
ensure that the total number of cells per well was not impeding the cells’ ability to divide
comfortably, but also to ensure that there were enough cells per well to achieve a stable
luminescence signal. Ideally, the transparent bottom of each well would be maximally
covered such that the largest number of cells per area could be treated. Concentrations
ranging from 250 cells/well to 25,000 cells/well (3,000 cells/cm2 – 300,000 cells/cm2)
were seeded and viability after 48 hours of incubation was compared by luminescence
(Figure 3). Wells containing more than 7500 cells/well at seeding produced luminescence
of approximately 3.5 x 104 RLU. As the relative luminescence peaked at this value, despite
the increasing cell concentration, it is likely that the wells either became too dense for
survival or the CellTiter-Glo was a limiting agent. As it is preferred for the relative
luminescence to be on the threshold such that the number of cells treated is as high as
possible without impairing growth, the relative luminescence of wells seeded at 250-1250
cells/well was too low. Wells seeded at 2500 cells/well and 5000 cells/well resulted in
luminescence just before the luminescence threshold at approximately 3.0 x 104 RLU and
3.3 x 104 RLU, respectively.
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Relative Luminescence (RLU)

45,000
40,000
35,000
30,000
25,000
20,000
15,000
10,000
5,000
0
0

5,000
10,000
15,000
20,000
Concentration at Seeding (cells/well)

25,000

Figure 3: Seed concentration of U138 cultured cells. Cells were lysed 48 h after seeding
and luminescence recorded. Error is standard deviation of quadruplicates.

Because the luminescence signal plateaued at 3.5 x 104 RLU, it was necessary to
ensure that the CellTiter-Glo was not the limiting agent in each reaction mixture. Volumes
of 25 – 50 µL of CellTiter-Glo reagent were added to wells containing 1.0 x 105 cells/well at
the time of seeding. Luminescence results show an inversely proportional relationship
between the volume of CellTiter-Glo and relative luminescence (Figure 4). Increasing the
volume of CellTiter-Glo may cause unnecessary competition or the added luciferase may
interfere with luminescence in some way. The results confirm that the 25 µL of CellTiterGlo is the optimal volume to produce peak luminescence.
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Relative Luminescence (RLU)
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Volume of Cell TiterGlo (µL)

45
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Figure 4: Determination of optimal volume of CellTiter-Glo used to lyse cells and show
luminescence relative to viability of cells in each well. Error is standard deviation of
triplicates.
Based on previous work, cells were incubated for 48 hours, as it takes
approximately 24 hours for cells to adhere to the well bottom, providing an additional 24
hours for cells number to double at least once. To confirm that 48 hours provides ample
time for cells to adhere and divide, wells were seeded with 1250 cells/well to 6250 cells/
well, as to try to avoid the threshold luminescence at 3.5 x 104 RLU. For up to 48 hours,
cells were lysed and luminescence recorded every 12 hours, then every 24 hours following
until 144 hours after seeding (Figure 5). The data appear to show that for lesser
concentrations, at 48 hours, luminescence is approximately double the luminescence at 0
hours, while for higher concentrations the luminescence is approximately 1.5 times the
luminescence at 0 hours. This may have resulted because it took longer for cells in wells
with higher concentrations to adhere to the well bottom due to competition for space and
nutrients to divide. At periods beyond 48 hours, error amongst triplicates became larger as
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luminescence varied by greater amounts, suggesting that cells were dividing at different
rates and the conditions in each well could not be controlled to maintain consistency.

NO Cells
1250 cells/well
2500 cells/well
3750 cells/well
5000 cells/well
6250 cells/well

Relative Luminescence (RLU)

100,000
80,000
60,000
40,000
20,000
0
0

24

48
72
96
Incubation Time (hr)

120

144

Figure 5: Determination of doubling time of U138 cultured cells. Wells were seeded with
various concentrations of cells and luminescence measured at multiple time points. Error is
standard deviation of triplicates.

However, despite error, the data suggest that cell doubling still occurs roughly every 48
hours until wells become too dense with cells. The wells seeded at 2500 cells/well show
approximate doubling after 48 hours, with considerably low error. After 48 hours, the
relative luminescence of the wells seeded at 2500 cells/well was 2.5 x 104 RLU, similar to
the relative luminescence emitted when determining the optimal seeding concentration.
The cells seeded in wells at 2500 cells/well duplicate in approximately 48 hours and error
increases markedly after 48 hours of incubation; seeding cells at 2500 cells/well with 48
15

hours of incubation prior to treatment produces the most precise conditions for the
chemical genetic screen.
At lethal dose, laromustine results in significant loss of viability in U138 cultured cells after 6
hours
The exact time after treatment for laromustine to enter cells and cause marked loss
in cell viability in U138 cultured cells is important to assess before completing the chemical
genetic screen. The drug requires time to enter the cell and begin to cause its deleterious
effects. The cell should respond to the treatment by trying to assuage the drug’s effects. The
series of events will not happen immediately, thus the amount of time for the drug to
significantly affect cells must be determined. This is done using a lethal dose of drug and
measuring the viability at various times after treatment. The viability of U138 cultured cells
was measured at different times from 10 min to 24 hours after treatment with lethal doses
of laromustine and temozolomide (Figure 6, 7). Within 6 hours of treatment, there was
significant loss of viability in the cells treated with laromustine compared to the DMSO
control, from 1.43 times within 3 hours of treatment to 0.20 times the control at 6 hours
after treatment. The viability of cells treated with laromustine continued to decrease in
subsequent hours, until the cells showed approximately 1% viability relative the DMSO
control. Similar results were observed in the cells treated with temozolomide, though
decreases in viability occurred 12 hours after treatment. Viability of cells treated with
temozolomide decreased to 10% relative the DMSO control after 12 hours but remained at
approximately 10% during subsequent hours.
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Relative Luminesence to DMSO
Control

2.5
2
1 mM Laromustine
1 mM Temozolomide

1.5
1
0.5
0
0

6

12
18
Time after Treatment (hr)

24

Figure 6: Determination of lethal dose time response of laromustine compared to
temozolomide. U138 cells were treated with 1000 µM laromustine and 1000 µM
temozolomide and luminescence determined at varying time points over course of 24
hours. Error is standard deviation of triplicates.

Relative Luminesence to DMSO
Control

2.5

1 mM Laromustine
1 mM Temozolomide

2
1.5
1
0.5
0
0

1

2
3
4
Time after Treatment (hr)

5

6

Figure 7: Determination of lethal dose time response of laromustine compared to
temozolomide. Shows data from Figure 5a in greater detail from 0 to 6 hours after
treatment. Error is standard deviation of triplicates.
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The cells treated with laromustine showed significant loss of viability within 6 hours
of treatment. This provides evidence that laromustine requires 6 hours of incubation
following treatment to drastically affect cells and impede their ability survive and
duplicate. Laromustine may be causing loss of viability in U138 cells in both direct and
indirect ways. The high dose of the drug is cytotoxic to the cell, though the nature of the
drug’s acute toxicity is unknown. The drug may affect cells via its known method of
crosslinking DNA, impeding cells from replicating and forcing them into apoptosis.
Similarly, temozolomide causes significantly loss of viability within 12 hours of treatment.
At lethal doses, laromustine affects viability in half the amount of time, indicating that
laromustine is able to enter cells and cause harmful effects quicker than temozolomide.
Additionally, laromustine causes an increased loss of viability compared to temozolomide.
At 24 hours after treatment, laromustine showed 1.5% viability relative to the DMSO
control while temozolomide remained at 11.5% viability relative to the DMSO control. This
preliminary 10-fold difference in viability, within error, implies that laromustine may be
more effective in treating U138 cultured cells, though more results are necessary to
confirm.
The median lethal dose of laromustine in treating U138 cultured cells for 6 hours is 400 µM
A lethal dose of laromustine is shown to cause loss of viability such that cells remain
as little as 1% viable compared to DMSO control. In order to assess the effective synergistic
effects between laromustine and other compounds, a concentration of laromustine must be
found such that more than 1% viability remains. Ideally, a median lethal dose is found such
that cells are 50% viable after 6 hours of treatment relative to the DMSO control. Using a
median lethal dose allows for comparison of loss of viability among cells treated with solely
18

laromustine and cells treated with both laromustine and a separate compound. The median
lethal dose was determined by treating U138 cultured cells with a two fold dilution of
laromustine from 2000 µM to 1 µM and allowing 6 hours of incubation before lysing and

Fraction Control Viability

recording luminescence (Figure 8). Significant doses over 1000 µM are effective in

1
0.8
0.6
0.4
0.2
0
10

100
1000
[laromustine] (µM)

10000

Figure 8: Determination of LD50 of laromustine in treating cultured U138 cells. Curve fit
analysis shows LD50 of 708 µM. Data shown are of three trials.

drastically affecting cell viability, while doses below 250 µM were less effective. Data
analysis shows a sigmoidal curve with a median lethal dose of 708 µM. Previous studies
demonstrate that laromustine is effective at concentrations lower than 50 µM in treating an
AML cell line, HL60. The ability for the cell to protect itself against low levels of laromustine
provides motivation for the chemical genetic screen. It is plausible, that with an additional
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infecting agent, laromustine may be more effective in decreasing the viability of cultured
brain cancer cells at a lower dose.
Though not confirmed by laboratory work, laromustine and Temozolomide should act
synergistically in inducing cell death of U138 cells
As previously mentioned, Temozolomide should show synergistic effects with
laromustine due its ability to interference with AGT enzyme function. Decreasing the
effectiveness of AGT should allow for a larger molar quantity of crosslinking by
laromustine. Preliminary tests have shown that there is not an increased cell death when
using both laromustine and temozolomide together in relation to when using them
separately. While there is drastic cell death, results show that it is most likely related solely
to the action of laromustine, as the Temozolomide control of 1000 µM, a lethal dose, is not
proving to induce marked cell death. These results are still forthcoming and work will
continue to be done in the future. Despite a lack of confirmation with Temozolomide, the
chemical genetic screen has been fully optimized to compare cell death between
laromustine and laromustine in conjunction with a library of small molecules. Using the
data obtained from the screen, compounds showing synergistic effects with laromustine
can be verified, laromustine’s mechanisms of actions can be better understood, and the
possibility of more successful treatments of glioblastoma multiforme with laromustine can
be investigated.
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Future Work
Little work remains to complete this project. First, the small-scale combination with
Temozolomide must be completed. It is expected that Temozolomide and laromustine will
have synergistic effects due to their determinedly similar mechanisms of action and
Temozolomide’s ability to inhibit AGT. Once the test combination is completed, the
standard death for each compound in the NIH Clinical Collection will be determined, as
written below. Then, with the assistance of Professor Robert Wheeler at the University of
Maine Orono, the chemical genetic screen will be run to determine the cell death when
laromustine and compounds from the library are used in conjunction. The chemical genetic
screen will be conducted as described below. Based on the results of the screen, further
research can be done into the mechanisms of laromustine and the effectiveness of the
compounds that showed synergistic effects from the screen.
Determination of Standard Death for NIH Clinical Collection
Cells will be seeded at 2500 cells/well (30,000 cells/cm2) with 25 µL/well as
previously described in methods section and incubated for two days. At time t = 48 hr,
media will be aspirated and media containing one of each of the compounds from the NIH
Clinical Collection will be added to each well. At time t = 6 hr after seeding, 25 µL of
CellTiter-Glo reagent will be added to each well and relative luminescence obtained.
Chemical Genetic Screen using Laromustine and NIH Clinical Collection
Cells will be seeded at 2500 cells/well (30,000 cells/cm2) with 25 µL/well as
previously described in the methods section and incubated for two days. At time t = 48 hr,
media will be aspirated and media containing LD50 concentration of laromustine as well as
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one of each of the compounds from the NIH Clinical Collection is to be added to each well.
At time t= 6 hr after seeding, 25 µL of CellTiter-Glo reagent will be added to each well and
relative luminescence obtained. Combinations of drugs that show a decreased
luminescence than when laromustine and the NIH Clinical Collection separately will be
tested again as described, though in triplicate, to ensure validity of data.
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